Ind-swift Laboratories Ltd. · NSE:INDSWFTLAB
Ind-swift Laboratories — Q1 FY27 Earnings Presentation
29 slides from Ind-swift Laboratories's earnings presentation, Aug 17, 2026
Slide 1: Intimation letter to stock exchanges on investor presentation
Ref: ISLL:CH:2026 Date: 17th August, 2026 The President The Vice President, Corporate Relationship Department Listing Compliance Department, BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor 25th Floor, Dalal Street, Plot No. C/2, G-Block, Mum
Slide 2: Ind-Swift Laboratories Limited Investor Presentation
Ind - Swift Laboratories Limited Leading Finished Dosage Formulation Manufacturer INVESTOR PRESENTATION 1
Slide 3: Management Commentary
MANAGEMENT COMMENTARY “Q1FY27 has set a strong tone for the year, demonstrating clear momentum as we continue to build on our transformation from an API player into a focused FDF manufacturer. The Company delivered a strong quarter, with operating EBITDA improving 2.85x YoY to ₹33.32 crore and op. E
Slide 4: Evolution & Transformation Journey
EVOLUTION & TRANSFORMATION JOURNEY Ind-Swift Group | Strategic Evolution 1997 1998 2004 2005 2007 2011 2012-23 Inception of Setup of API US 2nd plant USFDA PMD / ANVISA Manufacturing Subsidiary commissioned Approval USFDA Approval Ind-Swift Facility Incorporated in Jammu Approval FDA Laboratories In
Slide 5: Ind-Swift Laboratories Ltd – The Before State
IND - SWIFT LABORATORIES LTD – “The Before State” DMFs Filed across 33 Therapeutic APIs across Team Size molecules categories Incorporated in 1995 as part of the Ind-Swift Group. 30+ 2500+ 481+ 18 Built as the Group’s dedicated API & CRAMS entity. Among India’s largest standalone API manufacturers L
Slide 6: Transaction Summary & Financial Reset
TRANSACTION SUMMARY & FINANCIAL RESET Synthimed Labs Transaction Summary Strategic Rationale Slump Sale : Transaction Value : Debt Elimination: Proceeds used to repay entire external debt API & CRAMS business sold to Synthimed Labs Pvt. Ltd. Balance Sheet Reset: Transition from a leveraged profile t
Slide 7: Post-Transformation Overview
POST - TRANSFORMATION OVERVIEW Post-Transformation Overview Key Metrics • Strategic exit from API & CRAMS through a ₹1,650 Cr slump sale, making ISLL net debt-free. 850+ 520+ 38+ • Ind-Swift Limited merged into Ind-Swift Laboratories Limited Product Approvals Years of (Effective 31 March 2024, NCLT-
Slide 8: Manufacturing Infrastructure
MANUFACTURING INFRASTRUCTURE Domestic Unit Global Business Unit (GBU) Derabassi, Punjab Samba, J&K • Strategic Status: 100% Export-Oriented Unit (EOU) - Primary revenue engine. • Scale: Spans ≈81,325 sq. meters. • Capabilities: Dedicated blocks for Oral Solid Dosages (Tablets, Capsules, Sachets). •
Slide 9: R&D Capabilities
R&D CAPABILITES Infrastructure & Capabilities • Dedicated Formulation R&D Centre in Panchkula, approved by DST (Govt. of India). • 60+ specialized scientists focused on Finished Dosage development. • Strong analytical capabilities: stability studies (ICH), data profiling & analytical method validati
Slide 10: Integrated Business Lines
INTEGRATED BUSINESS LINES Infrastructure International& Capabilities Engine (Global Business Unit) Domestic Engine (India Operations) Focus: High-Value Exports & Regulated Market Comprehensive Market Coverage via multiple Strategic Verticals • Dossier-driven model for regulated & semi-regulated mark
Slide 11: Diversified Markets & Clientele
DIVERSIFIED MARKETS & CLIENTELE 47% Europe 4% Canada 2% 4% C.I.S. Middle East 1% 18% 2% Mexico South East Asia FWA 3% UAE 5% 10% 3% Africa Australia LATAM 1% South Africa 10
Slide 12: Global Market Potential
GLOBAL MARKET POTENTIAL 80 Global CMO Market Overview (In USD Billions) 73.75 70 2024 2030 60 56.09 51.91 50 40 30.88 30 20 15.73 10.48 9 10 6.65 2.13 3.6 2.03 3.99 0.83 1.33 0 UAE South Africa Australia Middle East Canada Europe USA Source Source Source Source Source Source Source • Growing demand
Slide 13: Global Product Registrations
GLOBAL PRODUCT REGISTRATIONS 116 CIS + 9 Russia 11 Canada 130 Europe 47 GCC 50 UAE 152 South East Asia 209 Africa + FWA 209 Africa + FWA 152 South East Asia 80 Latin America 116 CIS + 9 Russia 80 Latin America 50 UAE 130 Europe 37 Australia 37 Australia 47 GCC 19 South Africa 11 Canada 6 New 6 New Z
Slide 14: Global Regulatory Landscape
GLOBAL REGULATORY LANDSCAPE Russia Canada United Germany Hungary Kingdom Geneva Hessen UAE Saudi Taiwan Oman India Australia Regulated Markets Emerging Markets UK-MHRA (United Kingdom). WHO-GMP (Geneva). TGA (Australia). MoH UAE. Health Canada (Canada). MoH Russia. ROF Germany MoH Oman HLfGP Hessen
Slide 15: Operational & Strategic Developments – Q1FY27
OPERATIONAL & STRATEGIC DEVELOPMENTS – Q1FY27 CDMO/ Own Brands Commercialized: CDMO partnerships/ Own brands with Viatris (Ireland, Europe), Manx (UK), and Arrotex (Australia) have been commercialized and are expected to contribute incremental revenue of ₹200–220 Cr in FY27. New Product Commercializ
Slide 16: Top Export Portfolio Mix
TOP EXPORT PORTFOLIO MIX Market Size Market Size Top Product Revenue Wise Breakup Products FY25 FY26 2024/25 2030-35 Source FY26 (INR Lakhs) (In USD Billions) (In USD Billions) Atorvastatin 4795.71 8549.74 11.86 19.09 Link 5.56% 5.89% Ezetimibe + 22.17% 2328.13 8077.82 3.5 5.6 Link 2.25% Atorvas 4.3
Slide 17: Quarterly Sales Breakup Segment Wise
QUARTERLY SALES BREAKUP SEGMENT WISE 70.00% 60.00% 57.20% 50.00% 48.00% 40.00% 30.00% 29.00% 26.64% 20.00% 10.00% 10.00% 6.41% 7.00% 6.14% 6.00% 3.61% 0.00% Branded Generics Ethical Division Contract Manufacturing (P2P) Own-Brands Contract Manufacturing Domestic Export Q1FY26 Q1FY27 16
Slide 18: Upcoming Product Launch
UPCOMING PRODUCT LAUNCH Projected Products Partner Market Commercialization Market Size Market Size Source Revenue Year 2024/5 (In USD Mn) 2030 (In USD Mn) (In USD Mn) Ibuprofen Sachet Viatris Europe 12.00 Commercialized 112.7 164.1 Link Clarithromycin Dry Viatris Europe 6.00 FY27 2152.2 3501.43 Lin
Slide 19: Key Catalyst & Initiatives
KEY CATALYST & INITIATIVES Global Demand Surge Domestic Consumption Boom • Global pharmaceutical market expected to reach • Indian pharma market projected to reach from USD 55 USD 2,350 Billion by 2030. Source Billion USD 130 Billion by 2030, CAGR 12.25%. Source • Strong generic drug demand across r
Slide 20: Growth Rationale / Future Outlook
GROWTH RATIONALE / FUTURE OUTLOOK • Viatris Commercialization (Commercialized) • Topline CAGR 20-25%, scaling from • Commercial supplies begin in 2026, ₹636 Cr to ₹1,200+ Cr by FY29. ₹200-220 Cr incremental revenue • CDMO to triple over 3 years (₹180 expected in FY27. Cr → ₹635.89 Cr) driven by • 40
Slide 21: Board of Directors
BOARD OF DIRECTORS Mr. N.R. Munjal Mr. Himanshu Jain Chairman and Whole Time Director Managing Director (Domestic Operations) • 40+ years of experience expanding the Group’s • 22+ years of experience specializing in project footprint across 85+ countries with offices in planning, financial strategy,
Slide 22: Executive Leadership Team
EXECUTIVE LEADERSHIP TEAM Mr. Varun Chabra Mr. Ravi Bhardwaj President – International Mr. Pardeep Verma Mr. Gagan Agarwal VP Corporate Affairs & CS Chief Financial Officer Corporate Quality Head Marketing • 35+ Years of Experience across • 25+ years exp, expanded Quality, formulation R&D & • 29+ ye
Slide 23: Key Financial Metrics (Standalone)
KEY FINANCIAL METRICS (STANDALONE) Total Revenue (INR Cr.) Operating EBITDA (INR Cr) & Operating PAT (INR Cr) & PAT Margins (%), excluding EBITDA Margins (%) Exc. Items 193.71 30. 00 35. 00 33.32 25. 00 24.68 177.06 30. 00 174.91 20. 00 19.22 25. 00 16.60 13.26% 20. 00 18.69 17.91% 15. 00 11.13% 15.
Slide 24: Key Financial Metrics (Standalone)
KEY FINANCIAL METRICS (STANDALONE) Total Revenue (INR Cr.) Operating EBITDA (INR Cr) & Operating PAT (INR Cr) & PAT Margins (%), excluding EBITDA Margins (%) Exc. Items 682.84 60. 00 50. 00 44.78 53.56 630.92 45. 00 50. 00 40. 00 35. 00 40. 00 8.42% 30. 00 7.04% 32.88 25. 00 30. 00 20. 00 5.85% 15.
Slide 25: Q1 FY27 Standalone Financial Highlights
Q1 FY27 STANDALONE FINANCIAL HIGHLIGHTS Particulars (INR Cr) Q3 FY26 Q4 FY26 Q1 FY27 Q-o-Q Change (%) Revenue 149.48 164.72 186.12 Operating other income 3.69 7.98 -0.03 Non operating other income 23.89 2.21 7.63 Total Revenue 177.06 174.91 193.71 10.75 Raw material expense 70.13 64.86 75.21 Employe
Slide 26: FY26 Standalone Financial Highlights
FY26 STANDALONE FINANCIAL HIGHLIGHTS Particulars (INR Cr) FY25 FY26 Y-o-Y Change (%) Revenue 549.65 612.64 Operating other income 12.53 23.25 Non operating other income 68.75 46.96 Total Revenue 630.92 682.84 8.23 Raw material expense 285 283.49 Employee benefit expense 115.33 136.33 Other expenses
Slide 27: Standalone Balance Sheet
STANDALONE BALANCE SHEET Equities & Liabilities (INR Cr) FY25 FY26 Assets (INR Cr) FY25 FY26 Shareholder's Fund Non Current Assets Share Capital 68.74 86.84 PP&E 272.97 316.19 Reserves & Surplus 1095.33 1283.86 Total Equity 1164.08 1370.70 Deferred tax assets 44.63 50.34 Other Non - Current Assets 3
Slide 28: Stock Data
STOCK DATA As on 14-08-2026 Stock Performance From 1st Apr 2025 To 14th Aug 2026 BSE: Stock Price ₹ 304.20 350 1000000 Market Capitalization ₹ Crs 2,645.37 Volume Close 900000 No. of Share Outstanding 8,69,61,558 300 Face Value ₹ 10.00 800000 52 Week High ₹ 320.25 250 700000 52 Week Low ₹ 87.00 6000
Slide 29: Thank You
Thank You ```` Investor & Public Relations Consultant Ind Swift Laboratories Ltd. SCO 850, NAC, Shivalik Enclave, 103-8, Lodha Eternis, MIDC, Manimajra, Chandigarh, Andheri East, Mumbai 400093 1600101, India Maharashtra, India. Phone: +91 9814131627 Phone: +91 85911 45959 Email: investor@indswiftlab
Ind-Swift Laboratories — Q1 FY27 Earnings Presentation on 6ix